Article

Toric IOL outperforms comparable spherical lens in FDA trial

San Diego - The AcrySof Toric IOL (Alcon Laboratories, Fort Worth, TX) is outperforming a comparable spherical IOL in uncorrected visual acuity (UCVA) levels and the low level of residual astigmatism. The interim safety and efficacy results of the FDA clinical trial of the AcrySof Toric IOL were presented here at the annual meeting of the American Society of Cataract and Refractive Surgery.

Related Videos
Image credit: Ophthalmology Times; EnVision Summit 2025: Sonia H. Yoo, MD, shares what to expect from the cataract and refractive agenda
Ophthalmology Times: Kathryn Colby, MD, PhD, reflects on National Women Physicians Day
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.